(MedPage Today) — Real-world data presented at the American Society of Clinical Oncology (ASCO) annual meeting reinforced the effectiveness and safety of bispecific antibodies for relapsed or refractory follicular lymphoma, including in patients…
Source: MedPage Today — Headlines
